Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination.

Fiche publication


Date publication

mars 2013

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Dr GODET Yann


Tous les auteurs :
Dosset M, Vauchy C, Beziaud L, Adotevi O, Godet Y

Résumé

Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target CD4+ helper T cells in vivo represent a powerful approach to fully exploit these cells for anticancer immunotherapy.

Référence

Oncoimmunology. 2013 Mar 1;2(3):e23430.